Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 51 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Pipeline Review, H1 2016', provides in depth analysis on Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) targeted pipeline therapeutics. 

The report provides comprehensive information on the Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22)
- The report reviews Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) Overview 6
Therapeutics Development 7
Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Products under Development by Stage of Development 7
Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Products under Development by Therapy Area 8
Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Products under Development by Indication 9
Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Products under Development by Companies 12
Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Products under Development by Universities/Institutes 14
Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Companies Involved in Therapeutics Development 21
Astex Pharmaceuticals, Inc. 21
Presage Biosciences, Inc. 22
Tiziana Life Sciences Plc 23
Tragara Pharmaceuticals, Inc. 24
Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Drug Profiles 25
AT-7519 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
milciclib - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
TG-02 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
voruciclib - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Dormant Projects 36
Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Discontinued Products 38
Cyclin-Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or CDK1 or EC 2.7.11.22) - Featured News & Press Releases 39
Jun 03, 2016: Presage Biosciences Appoints David Johnson to Board of Directors 39
Apr 19, 2016: Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition by Voruciclib and Proteasome Inhibitors Superior to Single Agents in Model of Triple Negative Breast Cancer 39
Oct 28, 2014: Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014 40
May 28, 2014: Tragara's TG02 is Highly Active in CLL Cells Derived from Patients who have Failed Treatment with Ibrutinib 41
May 14, 2014: Phase II data of Nerviano Medical Science's kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO 42
Apr 07, 2014: New Preclinical Data of Tragara's TG02 in Acute Leukemia at AACR Meeting in San Diego 42
Dec 06, 2013: New Preclinical Data of Tragara's TG02 in Multiple Myeloma and Leukemia to be Presented at ASH 2013 Annual Meeting 43
Dec 03, 2013: Tragara Initiates Clinical Study of TG02 in Combination with Carfilzomib in Multiple Myeloma 43
Sep 12, 2013: Tragara Announces Oral Presentation at Society of Hematology Oncology Annual Meeting 44
May 31, 2012: Tragara Describes Mechanism Of Action Of Anti-Tumor Drug TG02 44
May 22, 2012: Piramal Healthcare To Present Phase I Data For New Oral Anticancer Molecule At ASCO Annual Meeting 45
Apr 03, 2012: Piramal Healthcare To Present Preclinical Data On Tumor Drug P1446A-05 At 2012 AACR Annual Meeting 47
Apr 02, 2012: Tragara Pharma Announces Presentation Of Preclinical Data Of TG02 At 2012 AACR Annual Meeting 47
Sep 14, 2011: Tragara And Multiple Myeloma Research Foundation Initiate Phase I Clinical Study Of TG02 In Multiple Myeloma Patients 48
Mar 23, 2011: Tragara To Present TG02 Poster At 102nd AACR Annual Meeting 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

List of Tables

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Action, H1 2016 17
Number of Products by Stage and Route of Administration, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 20
Pipeline by Astex Pharmaceuticals, Inc., H1 2016 21
Pipeline by Presage Biosciences, Inc., H1 2016 22
Pipeline by Tiziana Life Sciences Plc, H1 2016 23
Pipeline by Tragara Pharmaceuticals, Inc., H1 2016 24
Dormant Projects, H1 2016 36
Dormant Projects (Contd..1), H1 2016 37
Discontinued Products, H1 2016 38